|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AADAC |
Gene summary for AADAC |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AADAC | Gene ID | 13 |
| Gene name | arylacetamide deacetylase | |
| Gene Alias | CES5A1 | |
| Cytomap | 3q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | P22760 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 13 | AADAC | Pat11-B | Human | Stomach | GC | 9.52e-10 | 1.47e-02 | -0.182 |
| 13 | AADAC | Pat12-B | Human | Stomach | GC | 1.82e-07 | -1.84e-01 | 0.0325 |
| 13 | AADAC | Pat15-B | Human | Stomach | GC | 6.85e-04 | -2.16e-01 | -0.0778 |
| 13 | AADAC | Pat16-B | Human | Stomach | GC | 7.34e-06 | -4.07e-01 | 0.1918 |
| 13 | AADAC | Pat18-B | Human | Stomach | GC | 3.62e-03 | -1.99e-01 | -0.0432 |
| 13 | AADAC | Pat22-B | Human | Stomach | GC | 3.81e-20 | -1.54e-02 | -0.1042 |
| 13 | AADAC | Pat24-B | Human | Stomach | GC | 1.65e-07 | 9.21e-02 | -0.1184 |
| 13 | AADAC | Pat25-A | Human | Stomach | CAG with IM | 5.66e-25 | -7.06e-02 | -0.1648 |
| 13 | AADAC | Pat26-A | Human | Stomach | CSG | 2.64e-23 | -5.67e-02 | -0.2402 |
| 13 | AADAC | Pat28-A | Human | Stomach | CSG | 5.89e-11 | 1.34e-01 | -0.2594 |
| 13 | AADAC | Pat29-A | Human | Stomach | CAG with IM | 9.48e-08 | 9.34e-02 | -0.2769 |
| 13 | AADAC | NAG_2 | Human | Stomach | CSG | 4.01e-02 | 2.16e-01 | -0.3324 |
| 13 | AADAC | WIM_1 | Human | Stomach | WIM | 3.66e-02 | -3.99e-01 | 0.0335 |
| 13 | AADAC | SIM_2 | Human | Stomach | SIM | 3.91e-06 | -4.26e-01 | 0.3139 |
| 13 | AADAC | SIM_4 | Human | Stomach | SIM | 1.99e-02 | 4.64e-01 | 0.2664 |
| 13 | AADAC | Pt1_Superficial | Human | Stomach | GC | 7.39e-03 | -4.34e-01 | 0.1036 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000989626 | Esophagus | HGIN | positive regulation of catabolic process | 126/2587 | 492/18723 | 1.46e-12 | 2.09e-10 | 126 |
| GO:003133126 | Esophagus | HGIN | positive regulation of cellular catabolic process | 112/2587 | 427/18723 | 5.15e-12 | 6.72e-10 | 112 |
| GO:0009896111 | Esophagus | ESCC | positive regulation of catabolic process | 332/8552 | 492/18723 | 4.36e-23 | 9.22e-21 | 332 |
| GO:0031331111 | Esophagus | ESCC | positive regulation of cellular catabolic process | 292/8552 | 427/18723 | 8.67e-22 | 1.53e-19 | 292 |
| GO:000941020 | Esophagus | ESCC | response to xenobiotic stimulus | 253/8552 | 462/18723 | 4.55e-05 | 3.58e-04 | 253 |
| GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
| GO:00442427 | Esophagus | ESCC | cellular lipid catabolic process | 121/8552 | 214/18723 | 8.63e-04 | 4.43e-03 | 121 |
| GO:00160427 | Esophagus | ESCC | lipid catabolic process | 168/8552 | 320/18723 | 7.97e-03 | 2.84e-02 | 168 |
| GO:00192168 | Esophagus | ESCC | regulation of lipid metabolic process | 172/8552 | 331/18723 | 1.20e-02 | 4.02e-02 | 172 |
| GO:00094106 | Stomach | GC | response to xenobiotic stimulus | 61/1159 | 462/18723 | 1.68e-08 | 1.43e-06 | 61 |
| GO:0006641 | Stomach | GC | triglyceride metabolic process | 23/1159 | 100/18723 | 3.27e-08 | 2.44e-06 | 23 |
| GO:0006639 | Stomach | GC | acylglycerol metabolic process | 24/1159 | 128/18723 | 9.59e-07 | 4.53e-05 | 24 |
| GO:0006638 | Stomach | GC | neutral lipid metabolic process | 24/1159 | 129/18723 | 1.11e-06 | 5.20e-05 | 24 |
| GO:00442424 | Stomach | GC | cellular lipid catabolic process | 32/1159 | 214/18723 | 3.16e-06 | 1.29e-04 | 32 |
| GO:00160425 | Stomach | GC | lipid catabolic process | 41/1159 | 320/18723 | 7.84e-06 | 2.80e-04 | 41 |
| GO:0019433 | Stomach | GC | triglyceride catabolic process | 9/1159 | 29/18723 | 4.19e-05 | 1.04e-03 | 9 |
| GO:0006805 | Stomach | GC | xenobiotic metabolic process | 19/1159 | 111/18723 | 4.79e-05 | 1.15e-03 | 19 |
| GO:00313316 | Stomach | GC | positive regulation of cellular catabolic process | 46/1159 | 427/18723 | 1.79e-04 | 3.12e-03 | 46 |
| GO:0019216 | Stomach | GC | regulation of lipid metabolic process | 37/1159 | 331/18723 | 3.67e-04 | 5.70e-03 | 37 |
| GO:00098966 | Stomach | GC | positive regulation of catabolic process | 50/1159 | 492/18723 | 3.89e-04 | 5.97e-03 | 50 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AADAC | SNV | Missense_Mutation | c.896N>G | p.Asn299Ser | p.N299S | P22760 | protein_coding | tolerated(0.68) | benign(0.001) | TCGA-A2-A0EU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| AADAC | SNV | Missense_Mutation | c.64C>T | p.Pro22Ser | p.P22S | P22760 | protein_coding | deleterious(0.02) | probably_damaging(0.931) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD | |
| AADAC | SNV | Missense_Mutation | novel | c.364C>G | p.Leu122Val | p.L122V | P22760 | protein_coding | tolerated(0.09) | benign(0.007) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| AADAC | SNV | Missense_Mutation | novel | c.1150N>T | p.Ser384Cys | p.S384C | P22760 | protein_coding | deleterious(0.01) | benign(0.014) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| AADAC | insertion | Frame_Shift_Ins | novel | c.926_927insGCCAGCTGGTCTCGAACTCCTGACCTCAAGCAATCCATACTTC | p.Lys310ProfsTer30 | p.K310Pfs*30 | P22760 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| AADAC | insertion | In_Frame_Ins | novel | c.127_128insCTTGCC | p.Ile43delinsThrCysLeu | p.I43delinsTCL | P22760 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| AADAC | insertion | Frame_Shift_Ins | novel | c.129_130insAACCCCGTCCCCACTTCCCAATG | p.Gln44AsnfsTer46 | p.Q44Nfs*46 | P22760 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| AADAC | insertion | In_Frame_Ins | novel | c.808_809insGGT | p.Val270delinsGlyLeu | p.V270delinsGL | P22760 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| AADAC | deletion | Frame_Shift_Del | c.631delN | p.Lys211AsnfsTer7 | p.K211Nfs*7 | P22760 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | |||
| AADAC | SNV | Missense_Mutation | c.482N>G | p.Tyr161Cys | p.Y161C | P22760 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |